메뉴 건너뛰기
The Lancet Respiratory Medicine
Volumn 4, Issue 1, 2016, Pages 8-10
What if we made stratified medicine work for patients?
Author keywords

[No Author keywords available]
Indexed keywords

DISEASE COURSE; EVIDENCE BASED MEDICINE; FIBROSING ALVEOLITIS; HEALTH CARE PLANNING; HEALTH PROGRAM; HUMAN; MEDICAL DECISION MAKING; MEDICAL LITERATURE; MEDICAL RESEARCH; NOTE; OXYGEN THERAPY; PATIENT CARE; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PULMONARY REHABILITATION; QUALITY OF LIFE; SEX DIFFERENCE; TREATMENT OUTCOME; TREATMENT PLANNING; CLASSIFICATION; IDIOPATHIC PULMONARY FIBROSIS; PROCEDURES;
EID: 84952927420     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(15)00499-3     Document Type: Note
Times cited : (10)
References (13)
  • 1
    • 84952895658 scopus 로고    scopus 로고
    • (accessed July 13, 2015).
    • Stratified medicine Medical Research Council, (accessed July 13, 2015). http://www.mrc.ac.uk/research/initiatives/stratified-medicine/.
    • Stratified medicine
  • 2
    • 84898815851 scopus 로고    scopus 로고
    • Stratified medicine: towards better treatment for disease
    • Bell J Stratified medicine: towards better treatment for disease. Lancet 2014, 383(suppl):S3-S5.
    • (2014) Lancet , vol.383 , pp. S3-S5
    • Bell, J.1
  • 3
    • 79952717349 scopus 로고    scopus 로고
    • ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management
    • Raghu G, Collard HR, Egan JJ, et al. ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011, 183:788-824.
    • (2011) Am J Respir Crit Care Med , vol.183 , pp. 788-824
    • Raghu, G.1    Collard, H.R.2    Egan, J.J.3
  • 4
    • 84901810710 scopus 로고    scopus 로고
    • INPULSIS Trial Investigators. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis
    • Richeldi L, du Bois RM, Raghu G, et al. INPULSIS Trial Investigators. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014, 370:2071-2082.
    • (2014) N Engl J Med , vol.370 , pp. 2071-2082
    • Richeldi, L.1    du Bois, R.M.2    Raghu, G.3
  • 5
    • 84901759236 scopus 로고    scopus 로고
    • A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis
    • King TE, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014, 370:2083-2092. ASCEND Study Group.
    • (2014) N Engl J Med , vol.370 , pp. 2083-2092
    • King, T.E.1    Bradford, W.Z.2    Castro-Bernardini, S.3
  • 6
    • 84878686854 scopus 로고    scopus 로고
    • Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis
    • Fingerlin TE, Murphy E, Zhang W, et al. Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nat Genet 2013, 45:613-620.
    • (2013) Nat Genet , vol.45 , pp. 613-620
    • Fingerlin, T.E.1    Murphy, E.2    Zhang, W.3
  • 7
    • 84930865108 scopus 로고    scopus 로고
    • Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study
    • Jenkins RG, Simpson JK, Saini G, et al. Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study. Lancet Respir Med 2015, 3:462-472.
    • (2015) Lancet Respir Med , vol.3 , pp. 462-472
    • Jenkins, R.G.1    Simpson, J.K.2    Saini, G.3
  • 8
    • 17444366160 scopus 로고    scopus 로고
    • Resisting medicines: a synthesis of qualitative studies of medicine taking
    • Pound P, Britten N, Morgan M, et al. Resisting medicines: a synthesis of qualitative studies of medicine taking. Soc Sci Med 2005, 61:133-155.
    • (2005) Soc Sci Med , vol.61 , pp. 133-155
    • Pound, P.1    Britten, N.2    Morgan, M.3
  • 9
    • 84883244153 scopus 로고    scopus 로고
    • Cancer patients' trade-offs among efficacy, toxicity, and out-of-pocket cost in the curative and noncurative setting
    • Wong YN, Egleston BL, Sachdeva K, et al. Cancer patients' trade-offs among efficacy, toxicity, and out-of-pocket cost in the curative and noncurative setting. Med Care 2013, 51:838-845.
    • (2013) Med Care , vol.51 , pp. 838-845
    • Wong, Y.N.1    Egleston, B.L.2    Sachdeva, K.3
  • 10
    • 0003771723 scopus 로고    scopus 로고
    • Wiley Blackwell, Oxford, C. Pope, N. Mays (Eds.)
    • Qualitative research in health care 2006, Wiley Blackwell, Oxford. third edition. C. Pope, N. Mays (Eds.).
    • (2006) Qualitative research in health care
  • 12
    • 69949090035 scopus 로고    scopus 로고
    • We need minimally disruptive medicine
    • May C, Montori VM, Mair FS We need minimally disruptive medicine. BMJ 2009, 11(339):b2803.
    • (2009) BMJ , vol.11 , Issue.339 , pp. b2803
    • May, C.1    Montori, V.M.2    Mair, F.S.3
  • 13
    • 58849149098 scopus 로고    scopus 로고
    • Time, self and the medication day: a closer look at the everyday work of 'adherence'
    • McCoy L Time, self and the medication day: a closer look at the everyday work of 'adherence'. Sociol Health Ill 2009, 31:128-146.
    • (2009) Sociol Health Ill , vol.31 , pp. 128-146
    • McCoy, L.1

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.